Guardant Health Inc

GH

Equity

ISIN US40131M1099 / Valor 43633454

NASDAQ (2024-11-21)

USD 30.98+0.98%

Guardant Health Inc
UMushroom community rating:

4.29 7 votes No rating yet

NegativeNeutralPositive

About company

Guardant Health Inc is a company that focuses on utilizing blood tests to provide valuable insights for improving clinical outcomes in cancer care. With over 500,000 tests performed by 12,000 doctors, their commercially available tests assist in treatment decisions for advanced cancer patients, monitoring treatment response, detecting residual and recurrent disease in early-stage cancer patients, and potentially screening for cancer before symptoms appear. Additionally, their products support pharmaceutical companies in developing innovative cancer therapies.

Summarized from source with an LLMView SourceSector: Healthcare

Gross Margin

Guardant Health Inc's non-GAAP gross margin for the second quarter of 2024 was 60%, compared to 62% in the corresponding prior year period. The non-GAAP gross margin excluding screening was 62% for the second quarter of 2024, down from 64% in the same period last year.

Operating Expenses

Operating expenses for Guardant Health Inc in the second quarter of 2024 were $205.4 million, slightly up from $202.9 million in the same quarter of the previous year. Non-GAAP operating expenses were $178.8 million, a slight decrease from $180.5 million in the prior year period.

Net Loss

Guardant Health Inc reported a net loss of $102.6 million for the second quarter of 2024, compared to a net loss of $72.8 million in the same period last year. The net loss per share was $0.84, up from $0.67 in the prior year period.

Adjusted EBITDA

The adjusted EBITDA loss for Guardant Health Inc in the second quarter of 2024 was $61.9 million, an improvement from the $85.2 million loss reported in the same quarter of the previous year.

2024 Guidance

Guardant Health Inc has updated its full-year 2024 revenue guidance, excluding screening, to be in the range of $690 to $700 million, representing a growth of 22% to 24% compared to 2023. The company continues to expect non-GAAP gross margin excluding screening to be between 61% and 63% for the full year.

Summarized from source with an LLMView Source

Key figures

35.2%1Y

-68.3%3Y

-60.7%5Y

Performance

70.7%1Y

75.1%3Y

67.8%5Y

Volatility